The reported GAAP net income is non-recurring and not indicative of core operations. Focus on the bota-vec regulatory filing timeline (2026) and the AAV2-hAQP1 Phase 2 AQUAx2 data readout (Q2 2027) as the primary catalysts. Monitor cash runway into H2 2028 and the $135M in potential near-term milestones from Lilly.
Price Chart
Executive Summary
MeiraGTx reported Q2 2026 GAAP net income of $160.7M ($1.71 diluted EPS) vs a net loss of $38.8M ($-0.48) a year ago, driven by $204.6M in license revenue from Reogen and $104.9M in related-party service revenue from the J&J termination. The company completed the bota-vec acquisition from J&J for $25M, secured up to $400M from Oberland Capital, and ended the quarter with $143.2M cash. The headline net income is non-recurring and driven by one-time license and termination revenues, while core R&D spend increased 73% to $57.8M reflecting the bota-vec reacquisition and AAV2-hAQP1 manufacturing costs. The stock will move on the bota-vec regulatory filing timeline and the AAV2-hAQP1 Phase 2 data readout in Q2 2027, not the reported earnings.
Key Financial Metrics
Key Facts
- Q2 2026 GAAP net income of $160.7M ($1.71 diluted EPS) vs net loss of $38.8M ($-0.48) in Q2 2025
- Total revenue of $321.4M, including $204.6M license revenue from Reogen and $104.9M service revenue from J&J termination
- Cash and cash equivalents of $143.2M at June 30, 2026, up from $65.9M at Dec 31, 2025
- Completed acquisition of bota-vec from J&J for $25M upfront cash payment
- Secured up to $400M strategic investment from Oberland Capital, with initial $135M funded
- Phase 2 AQUAx2 study for AAV2-hAQP1 completed enrollment; 12-month data readout on track for Q2 2027
- Anticipates global regulatory filings for bota-vec in 2026 and BLA filing for AAV2-hAQP1 in mid-2027
- R&D expenses increased to $57.8M from $33.5M, driven by bota-vec reacquisition and AAV2-hAQP1 manufacturing
Financial Impact
Q2 2026 GAAP net income of $160.7M is non-recurring, driven by $204.6M license revenue from Reogen and $104.9M service revenue from J&J termination. Core operating cash burn remains significant with R&D spend of $57.8M.
Risk Factors
- Clinical trial failure for AAV2-hAQP1 or bota-vec regulatory delays
- Dilution risk from the $100M equity offering and potential future equity issuances
- Execution risk in transitioning to a commercial-stage company
- Dependence on Oberland Capital and Lilly milestone payments for funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-095491 |
| Document: mgtx-20260813x8k.htm | 0001104659-26-095491 |
| Document: 0001104659-26-095491-index-headers.html | 0001104659-26-095491 |
| Document: 0001104659-26-095491-index.html | 0001104659-26-095491 |
| Document: 0001104659-26-095491.txt | 0001104659-26-095491 |
| 8-K Data (Synthetic) | 0001104659-26-095491 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 144 | $10.82 | awaiting T+60 | — | $9.40 (−13.12%) |
Sep 24, 2026 4w ago | 3 | $10.91 | awaiting T+60 | — | $9.40 (−13.84%) |
Sep 23, 2026 4w ago | 8-K | $11.75 | awaiting T+60 | — | $9.40 (−20.00%) |
Aug 18, 2026 9w ago | 144 | $14.97 | awaiting T+60 | — | $9.40 (−37.21%) |
Aug 13, 2026 10w ago | 8-K | $12.67 | awaiting T+60 | — | $9.40 (−25.81%) |
Aug 13, 2026 10w ago | Press Release | $12.67 | awaiting T+60 | — | $9.40 (−25.81%) |
Jul 7, 2026 16w ago | 8-K | $14.66 $11.00 | ▼ −24.97% | ▼ −26.96% | $9.40 (−35.88%) |
May 19, 2026 22w ago | 144 | $9.58 $13.52 | ▲ +41.13% | ▲ +36.12% | $9.40 (−1.88%) |
May 14, 2026 23w ago | 8-K | $9.95 $13.02 | ▲ +30.85% | ▲ +27.27% | $9.40 (−5.53%) |
May 14, 2026 23w ago | Press Release | $9.95 $13.02 | ▲ +30.85% | ▲ +27.27% | $9.40 (−5.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers